Impact of Age, Frailty, and Dementia on Prescribing for Type 2 Diabetes at Hospital Discharge 2012-2016.

BACKGROUND: The risks of intensive blood glucose lowering may outweigh the benefits in vulnerable older people. OBJECTIVES: Our primary aim was to determine whether age, frailty, or dementia predict discharge treatment types for patients with type 2 diabetes (T2D) and related complications. Secondly, we aimed to determine the association between prior hypoglycemia and discharge treatment types. DESIGN, SETTING AND PARTICIPANTS: We conducted a cohort study involving 3,067 patients aged 65-99 years with T2D and related complications, discharged from Melbourne's Eastern Health Hospital Network between 2012 and 2016. MEASUREMENTS: Multinomial logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (CI) for the association between age, frailty, dementia and hypoglycemia, and being prescribed insulin-only, non-insulin glucose-lowering drugs (GLDs) or combined insulin and non-insulin GLDs compared to no GLD. International Classification of Diseases-10 codes were used to identify dementia status and prior hypoglycemia; frailty was quantified using the Hospital Frailty Risk Score. RESULTS: Insulin-only, non-insulin GLDs, combined insulin and non-insulin GLDs, and no GLDs were prescribed to 19%, 39%, 20%, and 23% of patients, respectively. Patients >80 years were less likely than patients aged 65-80 to be prescribed any of the GLD therapies, (eg. non-insulin GLDs [OR 0.67; 95%CI 0.55-0.82]), compared to no GLD. Similarly, high vs. low frailty scores were associated with not being prescribed any of the three GLD therapies, (eg. non-insulin GLDs [OR 0.63; 95%CI 0.45-0.87]). However, dementia was not associated with discharge prescribing of GLD therapies. Patients with a hypoglycemia-related admission were more likely than those not hospitalized with hypoglycemia to receive insulin-only (OR 4.28; 95%CI 2.89-6.31). CONCLUSIONS: Clinicians consider age and frailty when tailoring diabetes treatment regimens for patients discharged from hospital with T2D and related complications. There is scope to optimize prescribing for patients with dementia and for those admitted with hypoglycemia.

Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?

AIM: To determine the patterns and predictors of pharmacological treatment initiation for type 2 diabetes and whether treatment initiation is consistent with Australian clinical practice guidelines that recommend metformin monotherapy. METHODS: Individuals aged 40-99 years initiating a non-insulin type 2 diabetes medication between July 2013 and February 2018 were identified from a 10% random national sample of pharmacy dispensing data. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the predictors of initiating sulfonylurea monotherapy, non-guideline monotherapy and combination therapy compared with metformin monotherapy. Predictors included age, sex, initiation year and comorbidities determined using the Rx-Risk comorbidity index. RESULTS: Of the 47 860 initiators, [47% women, mean age 60.7 (sd 12.1) years], 85.8%, 4.6%, 1.9% and 7.7% received metformin monotherapy, sulfonylurea monotherapy, non-guideline monotherapy and combination therapy, respectively. Increasing age was associated with increasing odds of initiating sulfonylurea monotherapy and non-guideline monotherapy. Combination therapy initiation was less likely in women (OR 0.74, 95% CI 0.69-0.79) and people with more comorbidities (e.g. OR 0.36, 95% CI 0.29-0.44 for seven or more comorbidities vs. no comorbidities) but more likely in congestive heart failure (OR 1.42, 95% CI 1.22-1.65), cerebrovascular disease (OR 1.50, 95% CI 1.32-1.69) and dyslipidaemia (OR 1.29, 95% CI 1.19-1.40). CONCLUSION: Treatment initiation in Australia is largely consistent with clinical practice guidelines, with 86% of individuals initiating metformin monotherapy. Initiation on combination therapy was more common in men and in those with fewer comorbidities.

An intervention to develop repeat prescribing in community pharmacy.

BACKGROUND: Lack of review of patients' medications in repeat prescribing is common. This and other problems in repeat prescribing need to be addressed. Community pharmacists could be more proactive in the review of chronic medications. OBJECTIVE: The purpose of this study was to test the feasibility and effects of pharmacists' interventions in repeat prescribing. METHODS: The normal repeat prescribing process used at Kuopio University Pharmacy and in Kuopio Health Services was developed by an intervention which included a pharmacist's interview and the annual medication data of the patient that were both transferred to the prescribing physician. RESULTS: Physicians in the intervention group identified and solved patients' drug-related problems better than was the case in the comparison group with normal repeat prescribing. Over half the patients receiving repeat prescriptions had at least one drug-related problem. The physicians used more information sources to support repeat prescribing in the intervention system. CONCLUSIONS: Community pharmacists are able to improve the quality of physician's repeat prescribing by providing vital information.

Comparison of CT and fiberoptic video-endoscopy findings in congenital dysplasia of the external and middle ear.

Twenty-six ears (of 25 patients) with congenital dysplasia of the external and middle ear were studied with two different types of imaging technologies in order to find out if it is possible to improve the anatomical overview of the dysplastic middle ears by combining the imaging methods. All the 26 ears were studied with computed tomography (CT), which gave cross-sectional images of the tympanic cavity. A fiberoptic video-endoscope (FVE) was introduced through the nose and via the Eustachian tube into the middle ear so that the topographic view of the anatomical structures of the middle ear could be visualized. Some structures were visualized better with FVE than with CT and vice versa. We concluded that the combined information obtained from these two imaging technologies provided a better understanding of the structural anatomy of a congenital dysplastic middle ear.

Tympanoscope-assisted myringoplasty.

Thirty ears of 29 patients with different sized perforation of the tympanic membrane were operated on with the aid of rigid otoendoscopes. The technique has a significant novel feature: endoscopy of the tympanic cavity through a perforation with small tympanoscopes 1.7 mm in diameter with a 0%. The postoperative air-bone gap was less than 10 dB in 90% of the ears. It was concluded that tympanoscope-assisted myringoplasty is a reliable and simple procedure with the benefit of minimal trauma in healthy tissue and that it is a feasible approach for day-case surgery with an ordinary success rate of tympanic membrane closure and hearing results.

Pharyngeal patency caused by stimulation of the hypoglossal nerve in anaesthesia-relaxed patients.

Impaired function of the genioglossal muscle is the most frequent reason for upper airway obstruction during sleep. Functional electrical stimulation (FES) of the hypoglossal nerve may be used to push the tongue forward to release the obstruction. Anaesthesia-induced upper airway obstruction resembles the situation during obstructive sleep apnea (OSA) syndrome. In order to develop an implantable FES system for treatment of OSA, we stimulated the exposed hypoglossal nerve in 6 patients undergoing radical cancer surgery of the head and neck region. Tongue movements during stimulation were video filmed and the amount of unobstructed airway achieved with stimulation was estimated using the adjacent intubation tube as reference. In every case, stimulation created an unobstructed airway, larger than the intubation tube.